A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
← catalyst calendarNCT06067841 · readout in 1,100 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
140estimated
Sites
15
Countries
Canada, France, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-18 | actual | When the study began enrolling |
| Primary completion | 2029-08-24 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-07-27 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Intervention
- Drug: BMS-986460
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs)
measured Up to 112 weeks
Number of participants with serious adverse events (SAEs)
measured Up to 112 weeks
Number of participants with AEs meeting protocol defined dose limiting toxicity (DLT) criteria
measured Up to 28 days
Number of participants with AEs leading to study intervention discontinuation
measured Up to 104 weeks
Number of deaths
measured Up to 108 weeks
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed